Major news broke in the iPSC sector last week when Ncardia (Cologne, Germany) and Nanion Technologies (Munich, Germany) signed a joint marketing and sales promotion agreement. Under the terms of partnership, customers of the companies will get access to high-performance instrument platforms from Nanion, coupled with Ncardia’s portfolio of hiPSC-derived cardiac cell types and assay services. [Read more…]
Stem Cell News
BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.
As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.
Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.
Cryo-Cell Acquires CORD:USE for $14 Million, Enters Public Cord Blood Sector
On June 4, 2018, Cryo-Cell International announced it will be acquiring the hybrid public-private cord blood bank CORD:USE for $14 million. The acquisition’s purposes are to strengthen its cord blood banking services by entering the public cord blood sector and to solidify its role as an industry leader. Learn about the combined commercial entity of Cryo-Cell CORD:USE below.
Cryo-Cell CORD:USE | The Acquisition of CORD:USE
In this article:
Exosome Start-up ExoCoBio Inc. raises $26.7M in Series B Funding
-
ExoCoBio is the 4th largest funded exosome startup in the world
-
ExoCoBio is using the funding to advance its exosome pharmaceutical R&D and cosmeceutical business
SEOUL, South Korea, Sept. 12, 2018 — ExoCoBio Inc. announced that it recently raised about $27 million in its series B funding. Top tier Korean investors participated in this round, including Seven Tree Equity Partners, CSQUARED Global Asset Management, TS Investment Partners, K2 Investment, Intervest, KDB Capital, Atinum Investment, GU Equity Partners, QUANTUM Ventures Korea, Platinum technology Investment.
[Read more…]
Unicyte and Collaboration Partner Prof. Camussi Achieve Preclinical Milestone in Diabetes Program
Unicyte, a regenerative medicine unit of Fresenius Medical Care, and its collaboration partner Professor Camussi have published results in Stem Cell Reviews and Reports that a potential therapeutic strategy for diabetes is the transplantation of induced-insulin secreting cells.
The Global Disease Burden of Diabetes Mellitus
Diabetes mellitus is one of the most common diseases globally. Diabetes mellitus (DM), commonly referred to as diabetes, is a group of metabolic disorders in which there are high blood sugar levels over a prolonged period. With an aging population and surging rates of obesity, the incidence of this debilitating disease on the rise. [Read more…]
Stem Cells for Heart Failure? BioCardia’s CardiAMP Pairs Cells, Devices and Diagnostics
Circulation Research, the official journal of the American Heart Association, has highlighted a novel stem cell therapy approach developed by BioCardia. For those not familiar with BioCardia, the company specializes in developing regenerative biologic therapies to treat cardiovascular disease.
BioCardia has developed a stem cell technology that includes a novel method of administration, as well as a pre-procedure assay to achieve a comprehensive approach to heart failure. BioCardia’s CardiAMP and CardiALLO cell therapies are the Company’s biotherapeutic product candidates in clinical development.
In addition to providing Phase III 10-patient roll-incohort data for BioCardia’s CardiAMP device, the paper published by Circulation Research offers a comprehensive rationale of CardiAMP’s development as a treatment for heart failure. [Read more…]
- « Previous Page
- 1
- …
- 120
- 121
- 122
- 123
- 124
- …
- 145
- Next Page »